Interim report January – September 2023: STRONG MARGINS DESPITE WEAKER GROWTH

THIRD QUARTER 2023 (JUL – SEP)

Net sales amounted to SEK 210.2 million (205.1), an increase of 3 percent compared with the corresponding period in the preceding year. The previous year’s revenue included the large US order which was received in the second quarter of 2022, of SEK 39.4 million.

License revenue amounted to SEK 55.5 million (40.4) and accounted for 26 percent of net sales (20).

Operating profit amounted to SEK 50.7 million (42.7).

Net profit amounted to SEK 47.4 million (28.5), corresponding to earnings per share of SEK 0.93 (0.56).

Cash flow from operating activities amounted to SEK 53.1 million (9.5). As at September 30, 2023, cash and cash equivalents amounted to SEK 606.1 million (370.1).

FIRST NINE MONTHS OF 2023 (JAN – SEP)

Net sales amounted to SEK 655.6 million (552.4), an increase of 19 percent compared with the corresponding period in the preceding year.

Operating profit amounted to SEK 151.5 million (101.3).

Net profit amounted to SEK 136.0 million (71.5), corresponding to earnings per share of SEK 2.67 (1.41).

Cash flow from operating activities amounted to SEK 198.7 million (50.9).

Gothenburg, Sweden, November 9, 2023
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/investor-relations/

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

For further information, please contact:

Gisli Hennermark, CEO
Telephone: +46-70-420 83 00
E-mail: gisli.hennermark@surgicalscience.com

Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com

About Surgical Science Sweden AB (publ)

One of the biggest challenges within healthcare globally is reducing injuries incurred during care. Medical education and training are key, especially as a large part of the training can now be performed outside the operating room. Surgical Science is a world leader in the development of virtual reality simulators for evidence-based training. The simulators enable surgeons and other medical specialists to train and improve their psycho-motor skills and instrument handling before entering the clinical environment. Alongside its own products, Surgical Science works with simulation solutions for medical device companies that develop instruments for clinical use, such as robotic surgery.

Surgical Science has approximately 260 employees. The company is headquartered in Gothenburg, Sweden and also has operations in Tel Aviv, Israel, as well as in Stockholm, Sweden and in Seattle and Cleveland, US. Through sales offices in the US and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Shares in Surgical Science Sweden AB (publ) are traded on Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank.

This information is information that Surgical Science Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-11-09 07:30 CET.

Attachments

231109 Q32023 ENG

231109 Q32023 ENG